{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:31:00Z","timestamp":1792992660861,"version":"4.5.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/hjh.0b013e32832961ed","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T13:01:49Z","timestamp":1242910909000},"page":"941-946","source":"Crossref","is-referenced-by-count":28,"title":["Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials"],"prefix":"10.1097","volume":"27","author":[{"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verdecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Trimarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210208","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jacc.2004.10.069","article-title":"Recent hypertension trials: implications and controversies","volume":"45","author":"Williams","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"R2-6-20210208","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"R3-6-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R4-6-20210208","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.329.7477.1248","article-title":"Angiotensin receptor blockers and myocardial infarction","volume":"329","author":"Verma","year":"2004","journal-title":"BMJ"},{"key":"R5-6-20210208","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/eurheartj\/ehi574","article-title":"Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"26","author":"Strauss","year":"2005","journal-title":"Eur Heart J"},{"key":"R6-6-20210208","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB\u2013MI paradox","volume":"114","author":"Strauss","year":"2006","journal-title":"Circulation"},{"key":"R8-6-20210208","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/hrt.2006.107185","article-title":"More about the \u201cARB MI paradox\u201d","volume":"93","author":"Hall","year":"2007","journal-title":"Heart"},{"key":"R9-6-20210208","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/0003-4819-141-9-200411020-00011","article-title":"Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction","volume":"141","author":"Lee","year":"2004","journal-title":"Ann Intern Med"},{"key":"R10-6-20210208","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.hjh.0000194114.12228.16","article-title":"Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds","volume":"23","author":"Volpe","year":"2005","journal-title":"J Hypertens"},{"key":"R11-6-20210208","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/bmj.38595.518542.3A","article-title":"Angiotensin receptor blockers and risk of myocardial infarction: systematic review","volume":"331","author":"McDonald","year":"2005","journal-title":"BMJ"},{"key":"R12-6-20210208","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/eurheartj\/ehi445","article-title":"Do angiotensin II receptor blockers increase the risk of myocardial infarction?","volume":"26","author":"Verdecchia","year":"2005","journal-title":"Eur Heart J"},{"key":"R13-6-20210208","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1345\/aph.1E478","article-title":"Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations","volume":"39","author":"Epstein","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R14-6-20210208","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.105.594978","article-title":"Angiotensin receptor blockers do not increase risk of myocardial infarction","volume":"114","author":"Tsuyuki","year":"2006","journal-title":"Circulation"},{"key":"R15-6-20210208","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/HJH.0b013e328306ebe2","article-title":"Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis","volume":"26","author":"Reboldi","year":"2008","journal-title":"J Hypertens"},{"key":"R18-6-20210208","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin\u2013angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"R19-6-20210208","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(07)60669-2","article-title":"Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity\u2013mortality study","volume":"369","author":"Mochizuki","year":"2007","journal-title":"Lancet"},{"key":"R20-6-20210208","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"key":"R21-6-20210208","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1291\/hypres.28.307","article-title":"Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients","volume":"28","author":"Suzuki","year":"2005","journal-title":"Hypertens Res"},{"key":"R22-6-20210208","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R23-6-20210208","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R24-6-20210208","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"R25-6-20210208","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial \u2013 the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"R26-6-20210208","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"R27-6-20210208","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"R28-6-20210208","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R29-6-20210208","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"R30-6-20210208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R31-6-20210208","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"R32-6-20210208","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"R33-6-20210208","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"R34-6-20210208","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R35-6-20210208","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R36-6-20210208","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R37-6-20210208","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"R38-6-20210208","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"R39-6-20210208","first-page":"127","article-title":"World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists Collaboration.","volume":"16","year":"1998","journal-title":"J Hypertens"},{"key":"R40-6-20210208","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R41-6-20210208","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/01.BRS.0000065484.95996.AF","article-title":"Updated method guidelines for systematic reviews in the Cochrane Collaboration back review group","volume":"28","author":"van Tulder","year":"2003","journal-title":"Spine"},{"key":"R42-6-20210208","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R43-6-20210208","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R44-6-20210208","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","article-title":"Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention","volume":"46","author":"Verdecchia","year":"2005","journal-title":"Hypertension"},{"key":"R45-6-20210208","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archinte.166.7.787","article-title":"Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials","volume":"166","author":"Danchin","year":"2006","journal-title":"Arch Intern Med"},{"key":"R46-6-20210208","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.0000096609.73772.C5","article-title":"Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin\u2013angiotensin system","volume":"109","author":"Levy","year":"2004","journal-title":"Circulation"},{"key":"R47-6-20210208","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","article-title":"The AT2 receptor: a matter of love and hate","volume":"26","author":"Steckelings","year":"2005","journal-title":"Peptides"},{"key":"R48-6-20210208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"R49-6-20210208","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"R50-6-20210208","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-200905000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T02:02:58Z","timestamp":1618365778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-200905000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32832961ed","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}